Introduction

It is well known morning stiffness and arthralgia commonly affect peri- and postmenopausal women, often associated with mild swelling of the peripheral and distal interphalangeal joints (PIPs, DIPs), mimicking early rheumatoid arthritis (RA) or osteoarthritis (OA) [1,2]. What happened at peri- and post-menopausal stage? Estradiol levels will be fluctuated and depleted at these stages, respectively, in contrast to men. After menopause, estradiol level of women is going down to a third of level of men [3]. Lack of estradiol induces autoimmunity through activation of NFkB [4,5]. This arthralgia consists primarily of pain on motion and tenderness; a diagnosis of undifferentiated arthritis based on a score of less than 5 by the ACR/EULAR criteria for the diagnosis of early RA is usually made [6]. Recently, it was reported that almost half RA diagnosis are misdiagnosed and proper diagnosis in most cases were OA or menopausal arthralgia suspected [7].
In this study, we presented typical two cases responded to hormone replacement therapy, although they were initially diagnosed as an early stage of RA and autoimmune rheumatic disease.

Case 1 was born in 1960. Her menopause was noted at a 46-year-old in 2004. She noticed numbness on peripheral joints and could not sleep well in 2008. She visited my clinic because of peripheral joint pains and elbow joint pain. Her blood test showed CRP 0.03, RF 50U, anti-CCP Ab 9.2U, E2 less than 11.8 and FSH 88.4 in May 2014 and ANA 160 homogenous, which was proved as anti-DFS Ab positive (50.5 Index) later.

HRT started immediately and her joint pain was reduced to 39% at one month later, and 7% at 10 months later. However, she newly complained of left wrist joint pains in August in 2018 and X ray showed bone erosion associated with radiocarpal joint space narrow and received 8mg weekly. Her pain was gradually reduced in December (Supplement Figure 1).

Case 2 was born in 1972. She received Kaufmann therapy from 2010 to 2014, but it ended treatment because of no improvement, and she was diagnosed as menopause. She started feeling uncomfortable at the fingers joints and increasing the number of hair loss. She got tired and hard to get up in 2015. She visited at orthopaedic clinic because of evaluation of increasing joint pain in Autumn 2016. Her blood examination revealed CRP 0.03, RF 5, Anti-CCP 3, MMP3 36.8 and ANA 40 homogenous in March 2018. However, she was diagnosed as a RA because of a new erosion and recommended to receive biologic DMARD by Rheumatologist. She moved my clinic in August 2018. HRT started immediately, her joint pains was reduced to 50% one month later and 20% in December 2018. (Supplement Figure 2). Her ANA going up to 160 with homogenous staining was proved anti-DFS Ab 80.0 Index positive.

These cases were initially diagnosed as having RA and received MTX at previous rheumatologists, but they wondered whether these joint pains were related to menopause or not. There are so many women presenting peripheral joint pains, sometimes with big joints. We explored to evaluate UA at peri-and post-menopausal stage.
Supplement Figure 2: Clinical and laboratory finding of Case 2.

In March 2018, her blood examination revealed CRP 0.03, RF 5, Anti-CCP 3, MMP3 36.8 and ANA 40 homogenous. However, she was diagnosed as a RA because of a new erosion and recommended to receive biologic DMARD by Rheumatologist. She moved my clinic in August 2018. HRT started immediately, her joint pains was reduced to 50% one month later and 20% in December 2018. Her ANA going up to 160 with homogenous staining was proved anti-DFS70 Ab 80.0 Index positive.

Methods

Setting and patients

174 female ethnically Japanese patients aged between 36 and 77 who visited a single women's outpatient rheumatology clinic between January and September were screened (Figure 1). Inclusion criteria were female sex, menopausal symptoms, and undifferentiated arthritis, defined as tenderness in two or more joints and pain on joint motion, with or without morning stiffness. Patients meeting respective criteria for other pathology, such as rheumatoid arthritis (defined as ACR/EULAR criteria ≥6 points),
Sjogren’s syndrome (SJS) [8], systemic lupus erythematosus (SLE) [9], or systemic scleroderma (SSc) [10], were excluded. Patients with joint erosions on x-ray. Twenty-seven declined further involvement in the study. The remaining 82 were provided with a detailed explanation of the scope and purpose of the study and gave their written and/or oral consent prior to enrolment. This study was approved by the Ethics Board of the Society of Healthcare for Menopause and Aging in Yokohama, Japan.

Criteria for menopausal status

Criteria used to define postmenopausal state were one year since last menstruation, serum estradiol (E2) level of less than 20pg/ml (Chemilumi ACS-Estradiol-6, Siemens Healthcare Diagnostics), and follicle stimulating hormone (FSH) level greater than 30mIU/ml (Chemilumi ACS-FSH, Siemens Healthcare Diagnostics). Perimenopausal state was defined as age greater than 45 years, and irregular menstruation.

HRT Protocol

HRT was administered as per the Japanese Society of Menopause and Health Care guidelines [11]. In brief, postmenopausal women with past history of hysterectomy received estrogen replacement therapy using 17β estradiol patch (0.72mg)/2 days. Postmenopausal women without hysterectomy aged under 55 received estrogen (17β estradiol plaster) and progesterone (dydrogesterone 10mg) replacement therapy (EPT) with cyclic treatment, and those in this group over 55 received the same with continuous EPT. Eight women aged over 60 in this group received E3 at 1 to 2mg per day, plus progesterone (dydrogesterone 5mg) for 12 days every 6 months. Perimenopausal women received Tocopherol Nicotinate 600mg/day.

Study end-point criteria

All patients were assessed 2 months post treatment commencement. Patients with small joint involvement only and greater than 30% reduction in joint pain as defined by patient (p)-VAS scores were considered to have responded to treatment. Patients with large joint involvement (knee or elbow) were assessed at 6 months for fulfilment of the same criteria. All patients were considered to have a baseline p-VAS score of 100 at the start of the trial. Those who responded to treatment were reclassified as peri-, or postmenopausal arthralgia, respective to their menopausal status.

Results

Screening and enrolment

Clinical and serological results were used to make tentative diagnoses following two visits. Of the original 174 women screened, 6 were diagnosed with RA, 4 with depression with arthralgia, 6 with SJS, 12 with OA, 8 with localized SSc, 3 with fibromyalgia (FM), and 1 with polymyalgia rheumatica. 83 women remained classified as undifferentiated arthritis and were enrolled in the study, of whom were, 15 were perimenopausal, and 68 were postmenopausal.

Efficacy of HRT in postmenopausal UA

68 women with UA were classified as postmenopausal and received HRT. Of these, 30% or greater reduction in p-VAS, and were therefore diagnosed with postmenopausal arthralgia following treatment. Eight women over 60-year-old treated with E3 2mg/day were excluded because of lack elevation of E2. Therefore, Pre- and post-treatment E2, FSH, and p-VAS were obtained in 60 women.
Baseline levels of E2 and FSH in this group were 38.7±51.8 pg/ml and 67.5±34.0 mIU/ml, respectively, consistent with postmenopause. Following administration of HRT for two to six months, E2 and FSH levels were 92.2±73.0 (p < 0.0005) and 45.5±26.9 (p < 0.0041), respectively, indicating adequate recovery of hormone levels. p-VAS scores improved significantly from 100±6 to 30±21 (p<0.0001) (Figure 2) and most patients reported resolution of morning stiffness, within two weeks.

Efficacy of Tocopherol N in perimenopausal UA

Fifteen women with UA were classified as perimenopausal and were treated with tocopherol N. Of these, Pre-and post-treatment E2, FSH and p-VAS were obtained in 15 patients. Baseline E2 and FSH levels were 91.9±72.8 pg/ml and 31.2±32.8 mIU/ml, respectively. These results were consistent with perimenopause. Following administration of Tocopherol N for two to six months, E2 and FSH levels were 158.0 ±148.9 (p=0.0016) and 6.2±2.6 (p<0.05), respectively, indicating adequate treatment. p-VAS improved greatly from 100±0 to 31±3 (p = 0.0001). (Figure 3), indicating significant symptomatic relief in this group. However, these data were so small and E2, FSH and pVAS were not completed simultaneously that further study is needed.

Discussion

There has been little study of the relationship between arthralgia and menopause. However, as estrogenic is known to act as an inhibitor of the inflammatory response [12], it is worth considering whether serum estrogenic reduction during the peri- and postmenopausal period plays a role in promoting joint inflammation in women during this period. It has previously been shown that relative reduction in estrogenic levels induced transient activation of T- and B-lymphocytes, as well as production of inflammatory cytokines including IL-6 and TNFα [13] that are hallmarks of the chronic inflammatory response [14]. Clinically, mid-aged women having severe myalgia /arthralgia are associated with higher incidence of insomnia/depression, in contrast to having slight myalgia/arthralgia. These symptoms are closely related and may be induced by estrogen deficiency [15].

ACR/EULAR criteria 2010 for early stage are very useful for finding new patients with RA, however, this criterion was not concerned with menopausal arthralgia well. The swelling of joint pain is not required and tenderness or pain on motion is accepted for joint problems, leading to misdiagnosis of RA. Recently, 4780 RA patients following 3 years were reassessed and among them, 39.3% were misdiagnosed and 50.1% RA [7]. Misdiagnosed RA consisted of 50.1% with osteoarthritis (OA), 39.3% with unknown and only 10.6% with autoimmune rheumatic disease [16]. OA is also related to occur at menopausal stage but is rarely found in male around 50. OA may be mainly associated with estrogen deficiency. If so, 89.4% of misdiagnosed RA is mainly caused by estrogen deficiency.

In Japan, HRT is not used widely and limited in women’s health clinic, so only 2% of menopausal women received HRT, in contrast to 20~50% in USA Europe and Australia. Therefore, many menopausal women complained of peripheral joint pain, sometimes including big joints, visited the orthopaedic clinic or rheumatologist in the hospital and they wondered whether they had RA or not. When doctors could not make a final diagnosis,
menopausal women will have to go around a doctors shopping. In such situation, HRT will be recommended. If it works, they have a postmenopausal arthralgia/arthritis caused by estrogen deficiency [17], because estrogen supplementation mostly relieved joint pain in postmenopausal women.

Clinical association between UA and progression to RA has been reported frequently. Van der Helm-van Mil et al. [18] reported that approximately 40% of cases of UA progressed to RA within one year, 20% to other diseases, and the remaining 40% exhibited remission. Furthermore, Kaneko Y et al. [19], in their assessment of the sensitivity of the 2010 RA Classification Criteria found sensitivity reduced to 15.8% where patients were rheumatoid factor (RF) and anti-ccp antibody negative, in contrast with a baseline sensitivity of 73.5%.

As for anti-DFS 70 Ab, two demonstrated cases shown above had high titer of anti-DFS 70 Ab. After they received HRT, joint pains were reduced to 10~24% from maximum 100%, respectively. However, the first case having low titer of anti-CCP Ab developed RA, although four year’s receiving HRT. The existence of anti-DFS 70Ab was not protective for ongoing to RA in this case, under the treatment of HRT [20].

The pathogenesis of RA is complex, and much of this process remains to be determined. This study provides preliminary findings which indicate that estrogen may be of vital importance in the onset of this disease, and supplementation may provide significant symptomatic relief in peri- and postmenopausal women with UA. Further studies are needed to confirm these findings and explore possible use of HRT or Pills for the prevention of progression to RA in these patient groups [21,22].

Acknowledgement

The authors thank Dr Sousei Kou of Enoshima Women’s Clinic for discussion and encouragement. Earlier progress of this study was reported at the 60th Japanese College of Rheumatology conference in 2016.4.28. (Yokohama, Japan) and the 30th Clinic for discussion and encouragement. Earlier progress of this study was reported at the 60th Japanese College of Rheumatology conference in 2016.4.28. (Yokohama, Japan) and the 30th Clinic for discussion and encouragement. Earlier progress of this study was reported at the 60th Japanese College of Rheumatology conference in 2016.4.28. (Yokohama, Japan) and the 30th Clinic for discussion and encouragement.

References